Lonza has announced its successful acquisition of PharmaCell, a European cell and gene contract manufacturer.
Acquisition
“PharmaCell’s position in the market complements Lonza’s leadership position in the allogenic cell manufacturing market,” said Andreas Weiler, head of emerging technologies at Lonza. “This acquisition broadens Lonza’s capabilities in Europe and positions Lonza as the only contract development and manufacturing network, spanning the US, Europe and Asia.”
Primarily selected for its core expertise in autologous cell and gene therapy manufacturing, PharmaCell has manufactured the only two European-approved commercial cell therapy products. Autologous therapies use a patient’s own cells.
The CEO of PharmaCell, Alexander Vos, commented: “Over the last seven years, we have been able to contract many of the blue-chip cell therapy companies. I am proud of my team, which has been able to deliver high-quality GMP-manufacturing services in this emerging and challenging field.”